LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Search

West Pharmaceutical Services Inc

Cerrado

SectorSanidad

276.48 -1.52

Resumen

Variación precio

24h

Actual

Mínimo

275.56

Máximo

277.44

Métricas clave

By Trading Economics

Ingresos

8.2M

140M

Ventas

38M

804M

P/B

Media del Sector

40.651

79.874

BPA

1.96

Rentabilidad por dividendo

0.31

Margen de beneficios

17.406

Empleados

10,600

EBITDA

19M

217M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+24.47% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.31%

2.31%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-56M

20B

Apertura anterior

278

Cierre anterior

276.48

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

168 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

West Pharmaceutical Services Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 nov 2025, 16:49 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 nov 2025, 15:32 UTC

Adquisiciones, fusiones, absorciones

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 nov 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 nov 2025, 23:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 nov 2025, 16:05 UTC

Charlas de Mercado

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 nov 2025, 16:04 UTC

Charlas de Mercado

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 nov 2025, 15:54 UTC

Adquisiciones, fusiones, absorciones

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 nov 2025, 15:44 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 nov 2025, 15:43 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 nov 2025, 15:42 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 nov 2025, 15:41 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 nov 2025, 15:11 UTC

Charlas de Mercado

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 nov 2025, 14:26 UTC

Charlas de Mercado

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 nov 2025, 14:11 UTC

Charlas de Mercado

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 nov 2025, 14:11 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 nov 2025, 13:35 UTC

Charlas de Mercado

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 nov 2025, 13:33 UTC

Charlas de Mercado

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 nov 2025, 13:22 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

27 nov 2025, 13:22 UTC

Charlas de Mercado

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 nov 2025, 13:17 UTC

Charlas de Mercado

LVMH Should Be Able to Recover Next Year -- Market Talk

27 nov 2025, 11:13 UTC

Charlas de Mercado

European Gas Prices Come Under Pressure -- Market Talk

27 nov 2025, 11:07 UTC

Ganancias

Genting: Positive About Prospects Over Longer Term

27 nov 2025, 11:06 UTC

Ganancias

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 nov 2025, 11:04 UTC

Ganancias

Genting: International Travel Demand Expected to Remain Resilient

27 nov 2025, 11:04 UTC

Ganancias

Genting: Global Growth Expected to Remain Subdued

27 nov 2025, 11:04 UTC

Ganancias

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 nov 2025, 10:59 UTC

Ganancias

Genting Bhd 3Q Net Profit Fell 86% on Year

27 nov 2025, 10:58 UTC

Ganancias

Genting Bhd 3Q Rev Rose 14% on Year

27 nov 2025, 10:56 UTC

Ganancias

Genting Bhd 3Q Net MYR30.3M

27 nov 2025, 10:56 UTC

Ganancias

Genting Bhd 3Q EPS MYR0.0079

Comparación entre iguales

Cambio de precio

West Pharmaceutical Services Inc previsión

Precio Objetivo

By TipRanks

24.47% repunte

Estimación a 12 Meses

Media 349.56 USD  24.47%

Máximo 375 USD

Mínimo 311 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para West Pharmaceutical Services Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

10

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

213.26 / 219.27Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

168 / 374 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its products include various primary packaging, containment solutions, reconstitution, and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services, and integrated solutions. The Company’s segments include Proprietary Products and Contract-Manufactured Products. Proprietary Products reportable segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services. Contract-Manufactured Products segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
help-icon Live chat